ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0341

Clinical Applications of Urine SERPINC1/ORM1 in MRL-lpr Lupus Nephritis-Prone Mice

YoungEun Kim1, Eun-Ju Lee1, Soo Min Ahn1, Ji Seon Oh2, Seokchan Hong1, Chang Keun Lee1, Bin Yoo1 and Yong Gil Kim1, 1Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, 2Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Lupus nephritis, Mouse

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Despite improvements in the treatment of lupus nephritis (LN), the prognosis remains unsatisfactory, and a need for non-invasive biomarkers for early detection endures. Previously, the usefulness of Serpin peptidase inhibitor clade C (antithrombin) member 1 (SERPINC1) and alpha-1-acid glycoprotein (ORM1) have been proposed as urine biomarkers for LN diagnosis through proteomics studies. However, their usefulness at the early disease stage has not yet been elucidated.

This study investigated the utility of urine SERPINC1 and ORM1 as early biomarkers for LN in the MRL-lpr mice, murine models of LN.

Methods: Urine samples were collected from MRL-lpr and MRL/MpJ mice at ages 13 and 23 weeks. Urine SERPINC1, ORM1, creatinine, and albumin were analyzed using an enzyme-linked immunosorbent assay (ELISA). Levels of urine SERPINC1, ORM1, and albumin were corrected with creatinine concentration. Kidney biopsies of both sets of mice at 23 weeks were performed, and expression of ORM1 and SERPINC1 in kidney tissues was determined by opal multiplexed immunofluorescent staining. The activity and chronicity in kidney pathology were measured by an animal pathologist.

Results: A total of twenty-three of MRL-lpr (n=12) and MRL/MpJ (n=11) mice underwent analysis. Serum anti-dsDNA increased significantly in MRL-lpr mice according to the number of weeks compared with MRL-MpJ mice (Figure 1). The amount of urine SERPINC1 and ORM1 detected by ELISA was significantly higher in MRL-lpr mice than in MRL/MpJ mice at 13 and 23 weeks (SERPINC1: p< .01 and p< .001 at 13 and 23 weeks, respectively; ORM1: p< .01 at 13 and 23 weeks) (Figure 2). In contrast, no significant difference in urine albumin was observed between the two groups at 13 weeks (p=.83); however, a difference was detected at 23 weeks (p< .001). Regarding the kidney pathology of MPL-lpr mice, urine ORM1 had a significantly positive correlation with the activity index (rho =.879, p< .001) and chronicity index (rho =.947, p< .001). The correlation with the histopathology index was stronger than with urine albumin, the activity index (rho =.807, p=.003), and the chronicity index (rho =.869, p=< .001). SERPINC1 and ORM1 were primarily expressed in the tubular membrane in immunofluorescent-stained kidney tissue (Figure 3).

Conclusion: Urine SERPINC1 and ORM1 were detected in the LN murine model earlier than albumin. Additionally, urine ORM1 correlated with the degree of activity and chronicity index more than urine albumin. Therefore, we suggest urine SERPINC1 and ORM1 as novel biomarkers for early LN.

Supporting image 1

Analysis of serum anti-dsDNA levels in mice

Supporting image 2

Comparative analysis of urine SERPINC1 and ORM1, and albumin level (A) urine SERPINC1 (B) urine ORM1 (C) urine albumin

Supporting image 3

Opal multiplexed immunofluorescent images; the expression of SERPINC1 and ORM1 in kidney tissue


Disclosures: Y. Kim, None; E. Lee, None; S. Ahn, None; J. Oh, None; S. Hong, None; C. Lee, None; B. Yoo, None; Y. Kim, None.

To cite this abstract in AMA style:

Kim Y, Lee E, Ahn S, Oh J, Hong S, Lee C, Yoo B, Kim Y. Clinical Applications of Urine SERPINC1/ORM1 in MRL-lpr Lupus Nephritis-Prone Mice [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/clinical-applications-of-urine-serpinc1-orm1-in-mrl-lpr-lupus-nephritis-prone-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-applications-of-urine-serpinc1-orm1-in-mrl-lpr-lupus-nephritis-prone-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology